Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: Results from an international registry
Date
2020Author
Brenner, Erica J.
Ungaro, Ryan C.
Gearry, Richard B.
Kaplan, Gilaad G.
Kissous-Hunt, Michele
Lewis, James D.
Ng, Siew C.
Rahier, Jean-Francois
Reinisch, Walter
Ruemmele, Frank M.
Steinwurz, Flavio
Underwood, Fox E.
Zhang, Xian
Colombel, Jean-Frederic
Kappelman, Michael D.
Metadata
Show full item record
Documentos PDF
Imagenes y Videos
Abstract
Coronavirus Disease 2019 (COVID-19), caused by
severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), was first reported in December 2019 and has
rapidly spread throughout the world leading to an international pandemic.1 Although most cases of COVID-19 are
mild, the disease can become severe and result in hospitalization, respiratory failure, or death with reported case
fatality rates ranging from 2.3% to 7.2%.2,3 To date, the
most frequently identified risk factors for severe COVID-19
have been age, cardiovascular disease, chronic lung conditions, obesity, and diabetes.2,4 In a recent report from the
United States, 78% of patients requiring intensive care unit
(ICU) admission had at least 1 underlying comorbidity
Palabras clave
COVID-19; TNF; Inflammatory bowel diseasesLink to resource
https://doi.org/10.1053/j.gastro.2020.05.032Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.